Neurocrine Biosciences Capital investments accrued but not yet paid decreased by 12.5% to $1.40M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 48.1%, from $2.70M to $1.40M. This is a positive signal — lower values indicate better performance for this metric.
An increase suggests rising future cash obligations related to capital projects, while a decrease indicates the settlement of these liabilities.
This metric tracks capital investments or property, plant, and equipment acquisitions that have been recognized as liabi...
Often found in the supplemental cash flow disclosures or accounts payable notes of capital-intensive firms.
other_capital_expenditures_incurred_but_not_yet_paid| Q2 '21 | Q4 '21 | Q1 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q4 '24 | Q1 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.10M | $1.60M | $2.80M | $600.00K | $200.00K | $100.00K | $1.60M | $1.10M | $2.20M | $1.40M | $2.70M | $1.60M | $1.40M |
| QoQ Change | — | -23.8% | +75.0% | -78.6% | -66.7% | -50.0% | >999% | -31.3% | +100.0% | -36.4% | +92.9% | -40.7% | -12.5% |
| YoY Change | — | — | — | -78.6% | — | — | — | +83.3% | >999% | -12.5% | +145.5% | +14.3% | -48.1% |